Inhibikase Therapeutics (IKT) to Release Quarterly Earnings on Tuesday

Inhibikase Therapeutics (NYSE:IKTGet Free Report) will issue its quarterly earnings data after the market closes on Tuesday, November 14th. Analysts expect the company to announce earnings of ($1.12) per share for the quarter. Parties interested in listening to the company’s conference call can do so using this link.

Inhibikase Therapeutics (NYSE:IKTGet Free Report) last issued its quarterly earnings data on Monday, August 14th. The company reported ($1.11) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.92) by ($0.19). Inhibikase Therapeutics had a negative return on equity of 83.69% and a negative net margin of 7,551.59%. The firm had revenue of $0.12 million for the quarter. On average, analysts expect Inhibikase Therapeutics to post $-4 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

Inhibikase Therapeutics Price Performance

Shares of NYSE:IKT opened at $1.00 on Friday. Inhibikase Therapeutics has a 12-month low of $0.79 and a 12-month high of $6.94. The business has a 50 day moving average of $1.24 and a 200-day moving average of $2.63. The stock has a market cap of $5.35 million, a PE ratio of -0.24 and a beta of 1.00.

Analysts Set New Price Targets

Separately, HC Wainwright reiterated a “buy” rating and issued a $27.00 price target on shares of Inhibikase Therapeutics in a research report on Tuesday, August 15th.

Get Our Latest Stock Report on Inhibikase Therapeutics

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of IKT. Barclays PLC acquired a new position in shares of Inhibikase Therapeutics during the second quarter worth $41,000. Renaissance Technologies LLC boosted its position in Inhibikase Therapeutics by 17.7% during the second quarter. Renaissance Technologies LLC now owns 221,900 shares of the company’s stock valued at $165,000 after acquiring an additional 33,431 shares during the last quarter. Blair William & Co. IL grew its stake in shares of Inhibikase Therapeutics by 20.5% in the 1st quarter. Blair William & Co. IL now owns 276,000 shares of the company’s stock valued at $181,000 after buying an additional 47,000 shares during the period. Vanguard Group Inc. increased its holdings in shares of Inhibikase Therapeutics by 10.7% during the first quarter. Vanguard Group Inc. now owns 530,098 shares of the company’s stock valued at $785,000 after acquiring an additional 51,394 shares in the last quarter. Finally, Armistice Capital LLC bought a new stake in shares of Inhibikase Therapeutics during the first quarter valued at approximately $1,947,000. 13.99% of the stock is currently owned by institutional investors and hedge funds.

Inhibikase Therapeutics Company Profile

(Get Free Report)

Inhibikase Therapeutics, Inc, a clinical-stage pharmaceutical company, develops therapeutics for Parkinson's disease and related disorders. Its lead product candidate is IkT-148009, a small molecule Abelson tyrosine kinase inhibitor, which is in Phase 2a clinical trials to the treatment of Parkinson's disease and gastrointestinal tract.

See Also

Earnings History for Inhibikase Therapeutics (NYSE:IKT)

Receive News & Ratings for Inhibikase Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inhibikase Therapeutics and related companies with's FREE daily email newsletter.